Quoin Pharmaceuticals, Ltd. (QNRX)
NASDAQ: QNRX · Real-Time Price · USD
0.319
-0.014 (-4.06%)
At close: Feb 21, 2025, 4:00 PM
0.321
+0.002 (0.63%)
After-hours: Feb 21, 2025, 7:47 PM EST
Quoin Pharmaceuticals Employees
Quoin Pharmaceuticals had 4 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
4
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$2,175,269
Market Cap
6.57M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 4 | 0 | - |
Dec 31, 2022 | 4 | 0 | - |
Dec 31, 2021 | 4 | 2 | 100.00% |
Dec 31, 2020 | 2 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 122,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
QNRX News
- 19 days ago - Quoin Pharmaceuticals Launches ‘NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure - GlobeNewsWire
- 4 weeks ago - Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome - GlobeNewsWire
- 4 weeks ago - Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies - Accesswire
- 6 weeks ago - Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study - GlobeNewsWire
- 2 months ago - Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering - GlobeNewsWire
- 2 months ago - Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study - GlobeNewsWire
- 2 months ago - Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies - GlobeNewsWire
- 4 months ago - Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024 - GlobeNewsWire